Arcus Biosciences (RCUS) Q4 2024 Annual Earnings
RCUS·Reported February 25, 2025·After market close
Arcus Biosciences reported Q4 2024 revenue of $26.0M, missed analyst consensus of $29.4M by $3.4M. Diluted EPS came in at $-1.03, beat the $-1.17 consensus by $0.14.
Revenue
$26.0Mmissed by $3.4M
Consensus: $29.4MDiluted EPS
$-1.03beat by $0.14
Consensus: $-1.17
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about Arcus Biosciences's Q4 2024 earnings report.
Arcus Biosciences (RCUS) reported Q4 2024 earnings on February 25, 2025 after market close.
Arcus Biosciences reported revenue of $26.0M and diluted EPS of $-1.03 for Q4 2024.
Revenue missed the consensus estimate of $29.4M by $3.4M. EPS beat the consensus estimate of $-1.17 by $0.14.
You can read the 10-K periodic report (0001724521-25-000040) directly on SEC EDGAR. The filing index links above go to sec.gov.